Current Report Filing (8-k)
January 06 2021 - 9:01AM
Edgar (US Regulatory)
0000876343
false
0000876343
2021-01-05
2021-01-06
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported): January 6, 2021
Lineage
Cell Therapeutics, Inc.
(Exact
name of registrant as specified in charter)
California
|
|
001-12830
|
|
94-3127919
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
No.)
|
2173
Salk Avenue, Suite 200
Carlsbad,
California
|
|
92008
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
(442)
287-8990
Registrant’s
telephone number, including area code
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
Common
stock
|
|
LCTX
|
|
NYSE
American
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act
of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
7.01. Regulation FD Disclosure.
Lineage
Cell Therapeutics, Inc. (“Lineage”) will participate in virtual meetings with analysts and investors
beginning January 6, 2021 and through the conclusion of the J.P. Morgan 39th Annual Healthcare Conference on January 14, 2021.
During those meetings, Lineage will use a presentation handout, which is furnished as Exhibit 99.1 and is incorporated herein
by reference. The presentation handout will also be made available in the “Investors” section of Lineage’s website,
located at investor.lineagecell.com.
Lineage
undertakes no duty or obligation to publicly update or revise the information contained in this report, although it may do so
from time to time through the filing of other reports or documents with the Securities Exchange Commission, through press releases,
or through other public disclosure, including in the “Investors” section of Lineage’s website. Lineage routinely
uses its website as a means of disclosing material non-public information and for complying with its disclosure obligations under
Regulation FD.
The
information in this Item 7.01 and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section
18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall
they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth
by specific reference in such filing.
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
Lineage
Cell Therapeutics, Inc.
|
|
|
|
Date:
January 6, 2021
|
By:
|
/s/
Chase C. Leavitt
|
|
Name:
|
Chase
C. Leavitt
|
|
Title:
|
General
Counsel and Corporate Secretary
|
Lineage Cell Therapeutics (AMEX:LCTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Lineage Cell Therapeutics (AMEX:LCTX)
Historical Stock Chart
From Sep 2023 to Sep 2024